CAMBRIDGE, Mass., July 16, 2025 - Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.